Variability of interalveolar septal remodeling after bleomycin treatment in mice

Ultrastructural Pathology

Volumn 29, Issue 1, 2005, Pages 53-64

  Polosukhin, Vasiliy V ^a   Stathopoulos, Georgios T ^a   Lawson, William E ^a,b   Blackwell, Timothy S ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atrophy; Electron microscopy; Fibrosis; Lung; Morphometry

Indexed keywords

BLEOMYCIN; COLLAGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CELL COUNT; CELL DAMAGE; CELL HYPERPLASIA; CELL STRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; INTERALVEOLAR SEPTAL REMODELING; LUNG ALVEOLUS EPITHELIUM; LUNG CAPILLARY; LUNG FIBROSIS; LUNG INJURY; LUNG INTERSTITIUM; LUNG PARENCHYMA; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLEOMYCIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; PULMONARY ALVEOLI; PULMONARY FIBROSIS;

EID: 15244352101     PISSN: 01913123     EISSN: None     Source Type: Journal    
DOI: 10.1080/019131290882286     Document Type: Article

References (35)

1. McAnulty RJ, Laurent GJ. Pathogenesis of lung fibrosis and potential new therapeutic strategies. Exp Nephrol. 1995;3:96-107.
2. Reynolds HY. Diagnostic and management strategies for diffuse interstitial lung disease. Chest. 1998;113:192-202.
3. Gross TJ, Hunnighake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345:517-525.
4. Nagai S, Nagao T, Hoshino Y, Hamada K. Heterogeneity of pulmonary fibrosis: interstitial pneumonias and sarcoidosis. Curr Opin Pulm Med. 2001;7:262-271.
5. Veeraraghavan S, Nicholson AG, Wells AU. Lung fibrosis: new classification and therapy. Curr Opin Rheumatol. 2001;13:5600-5604.
6. Crouch E. Pathobiology of pulmonary fibrosis. Am J Physiol. 1990;259:L159-L184.
7. Green HY. Overview of pulmonary fibrosis. Chest. 2002;122:334S-339S.
8. Razzaque MS, Taguchi T. Pulmonary fibrosis: Cellular and molecular events. Pathol Int. 2003;53:133-145.
9. Coalson JJ. The ultrastructure of human fibrozing alveolitis. Virchows Arch A [Pathol Anat]. 1982;395:181-199.
10. Fisher B, Morgenroth K. Ultrastructural study on human lung in alveolitis versus pulmonary fibrosis. Clin Invest. 1993;71:452-460.
11. Polosukhin VV. Anatomic Pathology of Inflammatory Lung Diseases (Ultrastructural Aspects of Destructive and Restoration Processes). Novosibirsk: Nauka; 1997 (in Russian).
12. Polosukhin VV. Ultrastructural study of the destructive and repair processes in pulmonary inflammation and following endobronchial laser therapy. Virchovs Arch. 1999;435:13-19.
13. Magro CM, Allen J, Pope-Harman A, et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol. 2003;119:556-567.
14. Reid LM. Needs for animal models of human diseases of the respiratory system. Am J Pathol. 1980;101:589-5101.
15. Kumar RK. Experimental models in pulmonary pathology. Pathology. 1995;27:130-132.
16. Adamson IYR, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77:185-198.
17. Lazo JS, Hoyt DG, Sebti SM, Pitt BR. Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmacol Ther. 1990;47:347-378.
18. Hay J, Schahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991;65:81-94.
19. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83:111-119.
20. Thrall RS, Barton RW, D'Amato DA, Sulavik SB. Differential cellular analysis of bronchoalveolar lavage fluid at various stages during the development of bleomycin-induced pulmonary fibrosis in the rat. Am Rev Respir Dis. 1982;126:488-492.
21. Schahzeidi S, Jeffery PK, Laurent GJ, McAnulty RJ. Increased type 1 procollagen mRNA transcripts in the lungs of mice during the development of bleomycin-induced fibrosis. Eur Respir J. 1994;7:1938-1943.
22. Weibel ER. Morphometry of the Human Lung. Berlin: Springer; 1963.
23. Taylor CR, Weibel ER. Design of the mammalian respiratory system, I: problem and strategy. Respir Physiol. 1981;44:1-10.
24. West JB, Mathieu-Costello O. Structure, strength, failure, and remodeling of the pulmonary blood-gas barrier. Annu Rev Physiol. 1999;61:543-572.
25. Kumar RK, Watkins SG, Lykke AW. Pulmonary responses to bleomycin-induced injury: an immunomorphologic and electron microscopic study. Exp Pathol. 1985;28:33-43.
26. Champman HA. Disorders of lung matrix remodeling. J Clin Invest. 2004;113:48-157.
27. Kawanami O, Ferrans VJ, Crystal RG. Structure of alveiolar epithelial cells in patients with fibrotic lung disorders. Lab Invest. 1982;46: 39-53.
28. Katzenstein A-L. Pathogenesis of "fibrosis" in interstitial pneumonia: an electron microscopic study. Hum Pathol. 1985;16:1015-1024.
29. Jones AW, Reeve NL. Ultrastructural study of bleomycin-induced pulmonary changes in mice. J Pathol. 1978;124:227-233.
30. Adler KB, Callahan LM, Evans JN. Cellular alterations in the alveolar wall in bleomycin-induced pulmonary fibrosis in rats: an ultrastructural morphometric study. Am Rev Respir Dis. 1986;133: 1043-1048.
31. Usuki J, Fukuda Y. Evolution of three patterns of intra-alveolar fibrosis produced by bleomycin in rats. Pathol Int. 1995;45:552-564.
32. Kasper M, Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol. 1996;11:463-483.
33. Pardo A, Selman M. Molecular mechanisms of pulmonary fibrosis. Front Biosci. 2002;7:d1743-d1761.
34. Gehr P, Bachofen M, Weibel ER. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol. 1978;32:121-140.
35. Maina JN. Structure, function and evolution of the gas exchangers: comparative perspectives. J Anat. 2002;201:281-304.